Slow start to the year as expected

Group sales stable at 14.389 billion euros (Fx & portfolio adj. minus 1.1 percent)o   Accelerated normalization in glyphosate business – good price dynamics in other Crop Science unitso   New Pharmaceuticals products deliver strong growth – headwinds in Chinao   Consumer Health continues to growEBITDA before special items: 4.471 billion euros (minus 14.9 percent)o   Glyphosate and inflation weigh on earningso   Pharmaceuticals maintains high R&D investmentCore earnings per share at 2.95 euros (minus 16.4 percent)Net income at 2.178 billion eurosFree cash flow at minus 4.102 billion eurosGroup outlook confirmed – target attainment at lower end of guidance Leverkusen...